Medicine and Health

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast cancer

D. Shi, Y. Li, et al.

Discover the findings of this pivotal study evaluating the cost-effectiveness of sacituzumab govitecan versus chemotherapy for HR+/HER2- metastatic breast cancer. Despite increased life-years and QALYs, the study reveals significant cost challenges, presenting an ICER of $612,772/QALY. This research, conducted by Demin Shi, Yan Li, Xueyan Liang, and Lingyuan Chen, highlights the urgent need for price reductions to enhance SG's feasibility.... show more

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

J. Cortés, S. A. Hurvitz, et al.

$Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA$

Medicine and Health

Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA

J. Yoon, J. Ahn, et al.

Medicine and Health

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

K. Shitara, Y. Bang, et al.

Medicine and Health

Breast Cancer Screening Using Clinical Breast Examination: A Cost-Effectiveness Analysis for South Africa

S. D. Masuku, O. Mandrik, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny